Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study

Clicks: 6
ID: 323390
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #32 of 169 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 169 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Oral finasteride is a cornerstone in the treatment of male androgenetic alopecia (AGA), yet concerns regarding systemic adverse events often limit patient adherence. Topical finasteride 0.25% has emerged as a promising alternative to minimize systemic exposure while maintaining local efficacy. Objectives To evaluate the effectiveness and safety of topical finasteride 0.25% as monotherapy in male patients with AGA over 52 weeks in a real-world setting. Methods A retrospective observational study was conducted at the Dermatology Unit of the University of Turin. Medical records of male patients treated with topical finasteride 0.25% monotherapy between April 2022 and November 2025 were reviewed. 123 adult men with AGA were included. Patients were evaluated at baseline (T0) and after 52 weeks (T52) using standardized clinical photography and videodermoscopy (VIDIX system), with paired intra-patient comparisons. Efficacy was assessed via trichoscopic changes in Total Hair Number (THN). Secondary outcomes included hair shaft thickness (HST), terminal-to-vellus hair ratio, Physician Global Assessment (PGA), patient-reported outcomes, and safety. Results A total of 123 male patients (mean age 32.4 ± 8.1 years) were included. At 52 weeks, significant increases in THN were observed in both the vertex (+21.8 hairs/cm2; P < 0.001) and temporal regions (+29.4 hairs/cm2; P < 0.001). Significant improvements were also noted in HST and the terminal-to-vellus ratio. The treatment was well tolerated; 7.3% of patients reported mild, transient local irritation. No systemic adverse events related to sexual function or mood were reported. Conclusions Topical finasteride 0.25% monotherapy demonstrates sustained clinical efficacy and a favorable safety profile after one year of treatment. These findings support its use as a viable therapeutic option for male AGA, particularly for patients reluctant to undergo systemic therapy.
Reference Key
openalex_W7172353947 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Giuseppe Gallo, Luca Mastorino, Pietro Quaglino, Simone Ribero
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag333
URL
https://doi.org/10.1093/ced/llag333
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.